In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.

Delivery of therapeutic agents via the pulmonary route has gained significant attention over the past few decades because this route of administration offers multiple advantages over traditional routes that include localized action, non-invasive nature and favorable lung-to-plasma ratio. However, assessment of post administration behavior of inhaled pharmaceuticals-such as deposition of particles over the respiratory airways, interaction with the respiratory fluid and movement across the air-blood barrier-is challenging because the lung is a very complex organs that is composed of airways with thousands of bifurcations with variable diameters. Thus, much effort has been put forward to develop models that mimic human lungs and allow evaluation of various pharmaceutical and physiological factors that influence the deposition and absorption profiles of inhaled formulations. In this review, we sought to discuss in vitro, in vivo and ex vivo models that have been extensively used to study the behaviors of airborne particles in the lungs and determine the absorption of drugs after pulmonary administration. We have provided a summary of lung cast models, cascade impactors, noninvasive imaging, intact animals, cell culture and isolated perfused lung models as tools to evaluate the distribution and absorption of inhaled particles. We have also outlined the limitations of currently used models and proposed future studies to enhance the reproducibility of these models.

[1]  C. Ehrhardt,et al.  Transport of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) in human respiratory epithelial cells. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  C. Lehr,et al.  Cell culture models of the respiratory tract relevant to pulmonary drug delivery. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[3]  M E Phelps,et al.  Positron emission tomography provides molecular imaging of biological processes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  N. Altorki,et al.  Tobacco smoke induces CYP1B1 in the aerodigestive tract. , 2004, Carcinogenesis.

[5]  A. Hickey,et al.  Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery , 2009, Pharmaceutical Research.

[6]  Dieter Hochrainer,et al.  Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[7]  Yi Wang,et al.  Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: Validation and application to brain imaging , 2010, Magnetic resonance in medicine.

[8]  S. Gettinger Targeted therapy in advanced non-small-cell lung cancer. , 2008, Seminars in respiratory and critical care medicine.

[9]  Jolyon P. Mitchell,et al.  Effect of Sampling Volume on Dry Powder Inhaler (DPI)-Emitted Aerosol Aerodynamic Particle Size Distributions (APSDs) Measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen Eight-Stage Cascade Impactor (ACI) , 2012, AAPS PharmSciTech.

[10]  G. Hoyle,et al.  Acute lung injury induced by chlorine inhalation in C57BL/6 and FVB/N mice. , 2008, Inhalation toxicology.

[11]  W. Shen,et al.  Conjugation with cationic cell-penetrating peptide increases pulmonary absorption of insulin. , 2009, Molecular pharmaceutics.

[12]  M. Cavet,et al.  Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells , 1997, Antimicrobial agents and chemotherapy.

[13]  R. Williams,et al.  Nebulization of mycophenolate mofetil inhalation suspension in rats: comparison with oral and pulmonary administration of Cellcept®. , 2013, International journal of pharmaceutics.

[14]  M. Everard Studies using radiolabelled aerosols in children. , 1994, Thorax.

[15]  C. Kim,et al.  Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. , 2000, Inhalation toxicology.

[16]  J. Murray,et al.  Respiratory clearance of aerosolized radioactive solutes of varying molecular weight. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  E. Haacke,et al.  Aerosol Delivery in Ventilated Newborn Pigs: An MRI Evaluation , 2008, Pediatric Research.

[18]  Eun Seong Lee,et al.  Antioxidant encapsulated porous poly(lactide-co-glycolide) microparticles for developing long acting inhalation system. , 2011, Colloids and surfaces. B, Biointerfaces.

[19]  F. Acevedo,et al.  Delivering horseradish peroxidase as a respirable powder to the isolated, perfused, and ventilated lung of the rat: the pulmonary disposition of an inhaled model biopharmaceutical. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[20]  A. Hickey,et al.  Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. , 2006, The Journal of antimicrobial chemotherapy.

[21]  R. Villenave,et al.  In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo , 2012, Proceedings of the National Academy of Sciences.

[22]  M. Matthay,et al.  Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs. , 2009, Chest.

[23]  M. Sakagami,et al.  Insulin Self-association: Effects on Lung Disposition Kinetics in the Airways of the Isolated Perfused Rat Lung (IPRL) , 2007, Pharmaceutical Research.

[24]  Michael Hindle,et al.  Numerical Model to Characterize the Size Increase of Combination Drug and Hygroscopic Excipient Nanoparticle Aerosols , 2011, Aerosol science and technology : the journal of the American Association for Aerosol Research.

[25]  G. Scheuch,et al.  Systemic treatment by inhalation of macromolecules--principles, problems, and examples. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[26]  D. Barends,et al.  An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol. , 2004, International journal of pharmaceutics.

[27]  R. Niven,et al.  Solute Absorption from the Airways of the Isolated Rat Lung. III. Absorption of Several Peptidase-Resistant, Synthetic Polypeptides: Poly-(2-Hydroxyethyl)-Aspartamides , 1990, Pharmaceutical Research.

[28]  L. Schanker,et al.  Absorption of sulphonamides and antitubercular drugs from the rat lung. , 1974, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  S. Matalon,et al.  Exposing animals to oxidant gases: nose only vs. whole body. , 2010, Proceedings of the American Thoracic Society.

[30]  K. Amighi,et al.  Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  A. Davis,et al.  Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. , 1991, Vaccine.

[32]  A. Ryrfeldt,et al.  Increasing exposure levels cause an abrupt change in the absorption and metabolism of acutely inhaled benzo(a)pyrene in the isolated, ventilated, and perfused lung of the rat. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[33]  M. Sakagami,et al.  In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. , 2006, Advanced drug delivery reviews.

[35]  E. Schwiebert,et al.  Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[36]  S. Ramalingam,et al.  Recent advances in targeted therapy for non-small cell lung cancer , 2007, Expert opinion on therapeutic targets.

[37]  G. Scheuch,et al.  Treatment of systemic diseases by inhalation of biomolecule aerosols. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[38]  C. Remuñán-López,et al.  Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[39]  E. Haacke,et al.  Effective aerosol delivery during high‐frequency ventilation in neonatal pigs , 2010, Respirology.

[40]  J. Zwischenberger,et al.  Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex vivo in respiratory drug delivery: an invited paper. , 2012, Advanced drug delivery reviews.

[41]  Ben Forbes,et al.  Human respiratory epithelial cell culture for drug delivery applications. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  C. Mazer,et al.  Treatment of pulmonary hypertension with selective pulmonary vasodilators , 2006, Current opinion in anaesthesiology.

[43]  R. Langer,et al.  Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Dolovich,et al.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. , 2003, British journal of clinical pharmacology.

[45]  F. Ahsan,et al.  Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator. , 2011, International journal of pharmaceutics.

[46]  Qun Wang,et al.  Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. , 2009, Journal of biomedical nanotechnology.

[47]  S. Newman,et al.  Scintigraphic assessment of therapeutic aerosols. , 1993, Critical reviews in therapeutic drug carrier systems.

[48]  F. Ahsan,et al.  Mutual Inhibition of the Insulin Absorption-Enhancing Properties of Dodecylmaltoside and Dimethyl-β-cyclodextrin Following Nasal Administration , 2001, Pharmaceutical Research.

[49]  A. Ryrfeldt,et al.  Vasoconstriction after inhalation of budesonide: a study in the isolated and perfused rat lung. , 2010, Pulmonary pharmacology & therapeutics.

[50]  G. Ferron Aerosol properties and lung deposition. , 1994, The European respiratory journal.

[51]  P. Worth Longest,et al.  Condensational growth of combination drug‐excipient submicrometer particles for targeted high‐efficiency pulmonary delivery: evaluation of formulation and delivery device , 2012, The Journal of pharmacy and pharmacology.

[52]  D Ganderton,et al.  Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. , 1999, Respiratory medicine.

[53]  S S Gambhir,et al.  Use of positron emission tomography in animal research. , 2001, ILAR journal.

[54]  S J Enna,et al.  Absorption of saccharides and urea from the rat lung. , 1972, The American journal of physiology.

[55]  Haibo Zhang,et al.  N-acetylcysteine attenuates ventilator-induced lung injury in an isolated and perfused rat lung model. , 2012, Injury.

[56]  D. Bhalla,et al.  Transport across rat trachea in vitro after exposure to cytoskeleton-active drugs in vitro or to ozone in vivo. , 1989, Experimental lung research.

[57]  Zhijun Yang,et al.  Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery , 2012, International Journal of Nanomedicine.

[58]  B. Alexander,et al.  Initial Characterization of Micafungin Pulmonary Delivery via Two Different Nebulizers and Multivariate Data Analysis of Aerosol Mass Distribution Profiles , 2009, AAPS PharmSciTech.

[59]  Abdo Kataya,et al.  Reducing bounce effects in the Andersen cascade impactor. , 2005, International journal of pharmaceutics.

[60]  L. Hope-weeks,et al.  PLGA Microparticles Encapsulating Prostaglandin E1-Hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) Complex for the Treatment of Pulmonary Arterial Hypertension (PAH) , 2011, Pharmaceutical Research.

[61]  C O'Callaghan,et al.  The science of nebulised drug delivery , 1997, Thorax.

[62]  M. Patterson,et al.  Quantitative fluorescence imaging of point-like sources in small animals , 2008, Physics in medicine and biology.

[63]  G. P. Martin,et al.  Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors. , 2010, International journal of pharmaceutics.

[64]  Ashim K. Mitra,et al.  Pulmonary Delivery of Free and Liposomal Insulin , 1993, Pharmaceutical Research.

[65]  A brief history of gamma scintigraphy. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[66]  F. Ahsan,et al.  Pulmonary Delivery of Low Molecular Weight Heparins , 2004, Pharmaceutical Research.

[67]  I. Adamson,et al.  Acute pulmonary toxicity of urban particulate matter and ozone. , 1997, The American journal of pathology.

[68]  D. McRobbie,et al.  In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[69]  J. Renauld,et al.  Local and Systemic Immune Responses to Intratracheal Instillation of Antigen and DNA Vaccines in Mice , 2004, Pharmaceutical Research.

[70]  Hans Lennernäs,et al.  Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. , 2003, Journal of pharmaceutical sciences.

[71]  M. King,et al.  Effect of aerosolized uridine-5'-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. , 1999, American journal of respiratory and critical care medicine.

[72]  Paul Flecknell,et al.  Replacement, reduction and refinement. , 2002, ALTEX.

[73]  G. N. Rao,et al.  Particle Size Distribution of a Suspension Aerosol Using Andersen and Marple-Miller Cascade Impactors , 1997, Pharmaceutical Research.

[74]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[75]  R. Go,et al.  Cyclotrons and positron emission tomography radiopharmaceuticals for clinical imaging. , 1992, Seminars in nuclear medicine.

[76]  G. Mainelis,et al.  Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. , 2013, Journal of aerosol medicine and pulmonary drug delivery.

[77]  F. Ahsan,et al.  Synthesis and Evaluation of Pegylated Dendrimeric Nanocarrier for Pulmonary Delivery of Low Molecular Weight Heparin , 2009, Pharmaceutical Research.

[78]  L. Rasmussen,et al.  Oxidative damage to DNA by diesel exhaust particle exposure in co-cultures of human lung epithelial cells and macrophages. , 2012, Mutagenesis.

[79]  Cory J. Berkland,et al.  Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. , 2010, International journal of pharmaceutics.

[80]  Yannick Crémillieux,et al.  Aerosols and gaseous contrast agents for magnetic resonance imaging of the lung. , 2008, Contrast media & molecular imaging.

[81]  A. Clark,et al.  An isolated perfused rat lung preparation for the study of aerosolized drug deposition and absorption. , 1986, Journal of pharmaceutical sciences.

[82]  Gabriela Apiou-Sbirlea,et al.  The use of combined single photon emission computed tomography and X-ray computed tomography to assess the fate of inhaled aerosol. , 2011, Journal of aerosol medicine and pulmonary drug delivery.

[83]  S. Randell,et al.  Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance , 2007, Toxicologic pathology.

[84]  B. Shekunov,et al.  Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications , 2007, Pharmaceutical Research.

[85]  W. C. Cannon,et al.  The flow-past chamber: an improved nose-only exposure system for rodents. , 1983, American Industrial Hygiene Association journal.

[86]  F. Ahsan,et al.  Indication of transcytotic movement of insulin across human bronchial epithelial cells , 2006, Journal of drug targeting.

[87]  Chandan Thomas,et al.  Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside. , 2008, Journal of pharmaceutical sciences.

[88]  C. Cox,et al.  Intratracheal instillation versus intratracheal-inhalation of tracer particles for measuring lung clearance function. , 1997, Experimental lung research.

[89]  G. Rudolf,et al.  Short-term and long-term clearance of particles from the upper human respiratory tract as function of particle size , 1990 .

[90]  J. Patton,et al.  The lungs as a portal of entry for systemic drug delivery. , 2004, Proceedings of the American Thoracic Society.

[91]  T. Orton,et al.  Xenobiotic accumulation and metabolism by isolated perfused rabbit lungs. , 1973, The Journal of pharmacology and experimental therapeutics.

[92]  Peter Gehr,et al.  A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. , 2005, American journal of respiratory cell and molecular biology.

[93]  B. Olsson Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? , 1995, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[94]  J. Morris,et al.  Acute respiratory responses of the mouse to chlorine. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[95]  J. Heyder,et al.  Regional deposition and retention of particles in shallow, inhaled boluses: effect of lung volume. , 1999, Journal of applied physiology.

[96]  T. Wiedmann,et al.  Distribution of aerosols in murine obliterative bronchiolitis lungs by fluorescent imaging , 2012, Experimental lung research.

[97]  P. Fritz,et al.  The ex-vivo isolated, perfused human lung model: description and potential applications. , 1996, The Thoracic and cardiovascular surgeon.

[98]  M. Dorato,et al.  Overview of inhalation toxicology. , 1990, Environmental health perspectives.

[99]  A. Ryrfeldt,et al.  Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[100]  D. Piwnica-Worms,et al.  Technoreview: Molecular imaging of host–pathogen interactions in intact small animals , 2004, Cellular microbiology.

[101]  F. Ahsan,et al.  Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism. , 2010, Journal of pharmaceutical sciences.

[102]  Nicholas C. Miller,et al.  Effect of Drug Load and Plate Coating on the Particle Size Distribution of a Commercial Albuterol Metered Dose Inhaler (MDI) Determined Using the Andersen and Marple-Miller Cascade Impactors , 1997, Pharmaceutical Research.

[103]  R. Niven,et al.  Delivery of biotherapeutics by inhalation aerosol. , 1995, Critical reviews in therapeutic drug carrier systems.

[104]  I Gonda,et al.  The ascent of pulmonary drug delivery. , 2000, Journal of pharmaceutical sciences.

[105]  Chan‐Wha Kim,et al.  Human Insulin Microcrystals with Lactose Carriers for Pulmonary Delivery , 2009, Bioscience, biotechnology, and biochemistry.

[106]  M. Sakagami,et al.  The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[107]  W. Hering,et al.  Lung clearance of inhaled particles after exposure to carbon black generated from a resuspension system. , 1987, Environmental research.

[108]  Jolyon P Mitchell,et al.  Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[109]  J. Pauluhn Overview of testing methods used in inhalation toxicity: from facts to artifacts. , 2003, Toxicology letters.

[110]  Claus-Michael Lehr,et al.  An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[111]  Jolyon Mitchell,et al.  Analysis of cascade impactor mass distributions. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[112]  C. Liedtke Differentiated properties of rabbit tracheal epithelial cells in primary culture. , 1988, The American journal of physiology.

[113]  Svetlana Lyapustina,et al.  Relative Precision of Inhaler Aerodynamic Particle Size Distribution (APSD) Metrics by Full Resolution and Abbreviated Andersen Cascade Impactors (ACIs): Part 1 , 2010, AAPS PharmSciTech.

[114]  A. Hickey,et al.  Facilitation of Pulmonary Insulin Absorption by H-MAP: Pharmacokinetics and Pharmacodynamics in Rats , 2001, Pharmaceutical Research.

[115]  P. Worth Longest,et al.  Performance of Combination Drug and Hygroscopic Excipient Submicrometer Particles from a Softmist Inhaler in a Characteristic Model of the Airways , 2012, Annals of Biomedical Engineering.

[116]  J. Pauluhn,et al.  A simple approach to validation of directed‐flow nose‐only inhalation chambers , 2007, Journal of applied toxicology : JAT.

[117]  D. M. Olive,et al.  A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. , 2007, Analytical biochemistry.

[118]  L. Låstbom,et al.  A Novel Method to Aerosolize Powder for Short Inhalation Exposures at High Concentrations: Isolated Rat Lungs Exposed to Respirable Diesel Soot , 2004, Inhalation toxicology.

[119]  A. Khademhosseini,et al.  Bioengineering the Lung : Molecules , Materials , Matrix , Morphology , and Mechanics Computational and bioengineered lungs as alternatives to whole animal , isolated organ , and cell-based lung models , 2012 .

[120]  Richard B Thompson,et al.  MRI measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide nanoparticles. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[121]  H. Mehendale,et al.  The isolated perfused lung--a critical evaluation. , 1981, Toxicology.

[122]  Vasilis Ntziachristos,et al.  Small-animal optical imaging. , 2008, Journal of biomedical optics.

[123]  C. Kercsmar,et al.  Inhaled corticosteroids in asthma management. , 2008, Respiratory care.

[124]  Hak-Kim Chan,et al.  In vitro/in vivo comparisons in pulmonary drug delivery. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[125]  Effros Rm,et al.  Measurements of pulmonary epithelial permeability in vivo. , 1983, The American review of respiratory disease.

[126]  J. Malo,et al.  Chlorine-induced injury to the airways in mice. , 2003, American journal of respiratory and critical care medicine.

[127]  Richard B Thompson,et al.  Using MRI to measure aerosol deposition. , 2012, Journal of aerosol medicine and pulmonary drug delivery.

[128]  C. Cross,et al.  Expression of mucin synthesis and secretion in human tracheobronchial epithelial cells grown in culture. , 1990, American journal of respiratory cell and molecular biology.

[129]  G. P. Martin,et al.  Characterisation of a Carrier-Free Dry Powder Aerosol Formulation Using Inertial Impaction and Laser Diffraction , 2006, Pharmaceutical Research.

[130]  F. Ahsan,et al.  Inhalable lactose-based dry powder formulations of low molecular weight heparin. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[131]  S. Anderson,et al.  Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. , 1994, The European respiratory journal.

[132]  N. Zhang,et al.  Biodegradable solid lipid nanoparticle flocculates for pulmonary delivery of insulin. , 2012, Journal of biomedical nanotechnology.

[133]  H. Chan,et al.  Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. , 2010, Journal of pharmaceutical and biomedical analysis.

[134]  L. Blanch,et al.  Effects of vascular flow and PEEP in a multiple hit model of lung injury in isolated perfused rabbit lungs. , 2008, The Journal of trauma.

[135]  Ying-zheng Zhao,et al.  Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy , 2012, Acta Diabetologica.

[136]  B. Lehnert,et al.  NITRIC OXIDE AND NITROGEN DIOXIDE AS INDUCERS OF ACUTE PULMONARY INJURY WHEN INHALED AT RELATIVELY HIGH CONCENTRATIONS FOR BRIEF PERIODS , 1990 .

[137]  F. Ahsan,et al.  PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[138]  Svetlana Lyapustina,et al.  Non-impactor-Based Methods for Sizing of Aerosols Emitted from Orally Inhaled and Nasal Drug Products (OINDPs) , 2011, AAPS PharmSciTech.

[139]  F. Acevedo,et al.  Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. , 2013, Journal of aerosol medicine and pulmonary drug delivery.

[140]  G. Baum,et al.  Changes in mucociliary clearance during acute exacerbations of asthma. , 1992, The American review of respiratory disease.

[141]  Ching-Hua Wang,et al.  Pulmonary delivery of insulin by liposomal carriers. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[142]  R. Williams,et al.  Influence of particle size on regional lung deposition--what evidence is there? , 2011, International journal of pharmaceutics.

[143]  Shi Ke,et al.  Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. , 2007, Journal of biomedical optics.

[144]  S. Enna,et al.  Absorption of drugs from the rat lung. , 1972, The American journal of physiology.

[145]  P Hagedoorn,et al.  Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. , 2002, International journal of pharmaceutics.

[146]  M. Mintun,et al.  Quantitation of pulmonary transgene expression with PET imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[147]  S. Cryan,et al.  In vivo animal models for drug delivery across the lung mucosal barrier. , 2007, Advanced drug delivery reviews.

[148]  F. Ahsan,et al.  Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[149]  K. Brown,et al.  In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[150]  L S Schanker,et al.  Drug absorption from the lung. , 1978, Biochemical pharmacology.

[151]  P Worth Longest,et al.  Characterization of Nanoaerosol Size Change During Enhanced Condensational Growth , 2010, Aerosol science and technology : the journal of the American Association for Aerosol Research.

[152]  A. Hickey,et al.  Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation , 2009, Antimicrobial Agents and Chemotherapy.

[153]  M. Dolovich,et al.  18F-fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery. , 2009, Proceedings of the American Thoracic Society.

[154]  A. Gutleb,et al.  Potential of coculture in vitro models to study inflammatory and sensitizing effects of particles on the lung. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[155]  B. Wong Inhalation Exposure Systems: Design, Methods and Operation , 2007, Toxicologic pathology.

[156]  I. Dmochowski,et al.  Functionalized 129Xe contrast agents for magnetic resonance imaging. , 2010, Current opinion in chemical biology.

[157]  J Yu,et al.  Pulmonary drug delivery: physiologic and mechanistic aspects. , 1997, Critical reviews in therapeutic drug carrier systems.

[158]  J S Fleming,et al.  A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. , 1994, The British journal of radiology.

[159]  M. Sakagami,et al.  Cascade impactor practice for a high dose dry powder inhaler at 90 L/min: NGI versus modified 6-stage and 8-stage ACI. , 2009, Journal of pharmaceutical sciences.

[160]  P. Spieth,et al.  Pretreatment with perfluorohexane vapor attenuates fMLP-induced lung injury in isolated perfused rabbit lungs , 2010, Experimental lung research.

[161]  Di Shao,et al.  Characterization of Calu-3 cell monolayers as a model of bronchial epithelial transport: organic cation interaction studies , 2013, Journal of drug targeting.

[162]  J. Pauluhn Validation of an improved nose‐only exposure system for rodents , 1994, Journal of applied toxicology : JAT.

[163]  J. Conway Lung imaging - two dimensional gamma scintigraphy, SPECT, CT and PET. , 2012, Advanced drug delivery reviews.

[164]  Z. Tabka,et al.  Steady pressure-flow relationship in a cast of the upper and central human airways. , 1987, International journal of bio-medical computing.

[165]  J. Emami,et al.  Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats , 2010, Biopharmaceutics & drug disposition.

[166]  S. Gardner,et al.  Principles and clinical applications of positron emission tomography. , 1992, American journal of hospital pharmacy.

[167]  H C Yeh,et al.  Anatomic Models of the tracheobronchial and pulmonary regions of the rat , 1979, The Anatomical record.

[168]  Edwards Am,et al.  Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Snell NJC, Ganderton D. eds. Respir Med 1999; 93: 123-133. , 2000 .

[169]  P R Byron,et al.  A novel dosing method for drug administration to the airways of the isolated perfused rat lung. , 1988, Journal of pharmaceutical sciences.

[170]  Dongming Hwang,et al.  Three-dimensional simulations of airways within human lungs , 2007, Cell Biochemistry and Biophysics.

[171]  J. Harkema,et al.  The Nose Revisited: A Brief Review of the Comparative Structure, Function, and Toxicologic Pathology of the Nasal Epithelium , 2006, Toxicologic pathology.